Predictors of response to dipeptidyl peptidase‐4 inhibitors: evidence from randomized clinical trials

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Diabetes/Metabolism Research Reviews

• Publication date

  2011-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/dmrr.1184PMID 21309062
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Dipeptydil peptidase-4 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials.

  2010cited by this paper
• Efficacy and Tolerability of Vildagliptin in Patients with Type 2 Diabetes Inadequately Controlled with Metformin Monotherapy

  2009cited by this paper
• Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial

  2009cited by this paper
• Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes

  2009cited by this paper
• Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy

  2009cited by this paper
• Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study

  2009cited by this paper
• Fifty‐two‐week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy

  2009cited by this paper
• Management of type 2 diabetes: NICE guidelines.

  2009cited by this paper
• Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy

  2009cited by this paper
• Prevention of cardiovascular disease through glycemic control in type 2 diabetes: a meta-analysis of randomized clinical trials.

  2009cited by this paper
• Efficacy and safety of adding the dipeptidyl peptidase‐4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double‐blind, placebo‐controlled study

  2009cited by this paper
• Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24‐week, double‐blind, randomized trial

  2009cited by this paper
• Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial

  2009cited by this paper
• Alogliptin Use in Elderly People: A Pooled Analysis from Phase 2 and 3 Studies

  2009cited by this paper
• Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment‐naive patients with type 2 diabetes mellitus

  2009cited by this paper
• The Efficacy and Safety of Saxagliptin When Added to Metformin Therapy in Patients With Inadequately Controlled Type 2 Diabetes With Metformin Alone

  2009cited by this paper
• Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA1c without causing weight gain or increased hypoglycaemia

  2009cited by this paper
• Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Alogliptin in Patients With Type 2 Diabetes and Inadequate Glycemic Control

  2008cited by this paper
• Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea *

  2008cited by this paper
• GLP‐1: physiological effects and potential therapeutic applications

  2008cited by this paper
• Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency

  2008cited by this paper
• Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24‐week, double‐blind, randomized trial

  2008cited by this paper
• Comparison of different drugs as add-on treatments to metformin in type 2 diabetes: a meta-analysis.

  2008cited by this paper
• Management of cardiovascular disease in patients with diabetes: the 2008 Canadian Diabetes Association guidelines

  2008cited by this paper
• Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes *

  2008cited by this paper
• Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy

  2008cited by this paper
• Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes

  2008cited by this paper
• Effect of Initial Combination Therapy With Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, and Metformin on Glycemic Control in Patients With Type 2 Diabetes

  2008cited by this paper
• Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus.

  2008cited by this paper
• Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double‐blind, non‐inferiority trial

  2007cited by this paper
• American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus.

  2007cited by this paper
• Comparison of Vildagliptin and Rosiglitazone Monotherapy in Patients With Type 2 Diabetes

  2007cited by this paper
• Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug‐naïve patients with Type 2 diabetes

  2007cited by this paper
• Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis.

  2007cited by this paper
• Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24‐week, randomized, double‐blind study *

  2007cited by this paper
• Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo‐controlled study *

  2007cited by this paper
• Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes

  2007cited by this paper
• Vildagliptin in Drug-naïve Patients with Type 2 Diabetes: A 24-Week, Double-blind, Randomized, Placebo-controlled, Multiple-dose Study

  2007cited by this paper
• Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes

  2007cited by this paper
• Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin

  2007cited by this paper
• Efficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetes.

  2007cited by this paper
• Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

  2006cited by this paper
• Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.

  2006cited by this paper
• EFFICACY AND SAFETY OF

  2004cited by this paper
• European guidelines on cardiovascular disease prevention in clinical practice

  2004cited by this paper
• Effect of aging and diabetes on the enteroinsular axis.

  2001cited by this paper
• Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature.

  2000cited by this paper
• Bias in meta-analysis detected by a simple, graphical test

  1997cited by this paper
• Assessing the quality of reports of randomized clinical trials: is blinding necessary?

  1996cited by this paper
• Operating characteristics of a rank correlation test for publication bias.

  1994cited by this paper
• Ecological correlations and the behavior of individuals.

  1950cited by this paper

• Heterogeneous effect of saxagliptin on glucose fluctuation and β-cell function in T1DM: a multicentre, randomised trial.

  2026cites this paper
• Exploring the Role of Sitagliptin in the Management of Type 2 Diabetes Mellitus for the Elderly: A Narrative Review.

  2025cites this paper
• Endogenous GLP-1 levels play an important role in determining the efficacy of DPP-IV Inhibitors in both prediabetes and type 2 diabetes

  2022cites this paper
• Increasing Age Associated with Higher Dipeptidyl Peptidase-4 Inhibition Rate Is a Predictive Factor for Efficacy of Dipeptidyl Peptidase-4 Inhibitors

  2021cites this paper
• Dipeptidyl peptidase‐4 inhibitor, anagliptin, alters hepatic insulin clearance in relation to the glycemic status in Japanese individuals with type 2 diabetes

  2021cites this paper
• Glucose‐lowering action through targeting islet dysfunction in type 2 diabetes: Focus on dipeptidyl peptidase‐4 inhibition

  2021cites this paper
• Efficacy and Safety of Ertugliflozin in Patients with Overweight and Obesity with Type 2 Diabetes Mellitus

  2020cites this paper
• Risk of any hypoglycaemia with newer antihyperglycaemic agents in patients with type 2 diabetes: A systematic review and meta‐analysis

  2019cites this paper
• Development of a 13C Stable Isotope Assay for Dipeptidyl Peptidase-4 Enzyme Activity A New Breath Test for Dipeptidyl Peptidase Activity

  2019cites this paper
• What is the Most Appropriate Hypoglycemic Agent for Older Patients with Type 2 Diabetes Mellitus?

  2019cites this paper
• Clinical markers associated with glycaemic response to dipeptidyl peptidase‐4 inhibitor therapy

  2018cites this paper
• Management of Type 2 Diabetes Mellitus in the Elderly

  2018cites this paper
• Precision Medicine in Type 2 Diabetes: Clinical Markers of Insulin Resistance Are Associated With Altered Short- and Long-term Glycemic Response to DPP-4 Inhibitor Therapy

  2018cites this paper
• Pharmacogenetics of oral antidiabetic therapy.

  2018cites this paper
• Comparison of the Effects of Teneligliptin and Sitagliptin, Two Dipeptidyl Peptidase 4 Inhibitors with Different Half-Lives, on Glucose Fluctuation and Glucagon-Like Peptide-1 in Type 2 Diabetes Mellitus.

  2018cites this paper
• Effectiveness prediction of Evogliptin treatment in type 2 diabetes mellitus in russian-korean population

  2018cites this paper
• Safety and efficacy of long-term treatment with teneligliptin: Interim analysis of a post-marketing surveillance of more than 10,000 Japanese patients with type 2 diabetes mellitus

  2018cites this paper
• Factors Related to the Glucose-Lowering Efficacy of Dipeptidyl Peptidase-4 Inhibitors: A Systematic Review and Meta-Analysis Focusing on Ethnicity and Study Regions

  2017cites this paper
• DPP4 gene variation affects GLP-1 secretion, insulin secretion, and glucose tolerance in humans with high body adiposity

  2017cites this paper
• DPP4 inhibitors and cardiovascular outcomes: safety on heart failure

  2017cites this paper
• Saxagliptin Responder Analysis: A Pooled Analysis of 5 Clinical Trials

  2016cites this paper
• Predictive Factors for the Therapeutic Response to Concomitant Treatment with DPP-4 Inhibitors in Type 2 Diabetes with Short-Term Follow-Up

  2016cites this paper
• Efficacy and safety of linagliptin according to patient baseline characteristics: A pooled analysis of three phase 3 trials.

  2016cites this paper
• A genetic variant in GLP1R is associated with response to DPP-4 inhibitors in patients with type 2 diabetes

  2016cites this paper
• Clinical and genetic predictors of dipeptidyl peptidase-4 inhibitor treatment response in Type 2 diabetes mellitus.

  2016cites this paper
• Baseline Body Mass Index and the Efficacy of Hypoglycemic Treatment in Type 2 Diabetes: A Meta-Analysis

  2016cites this paper
• Effects of sitagliptin as initial therapy in newly diagnosed elderly type 2 diabetics: A randomized controlled study

  2016influential citation
• Efficacy of hypoglycemic treatment in type 2 diabetes stratified by age or diagnosed age: a meta-analysis

  2016cites this paper
• Identification of predictors of response to basal insulin and DPP4 inhibitors in patients with type 2 diabetes failing to other therapies

  2016cites this paper
• Precision medicine: The future in diabetes care?

  2016cites this paper
• Hot Topics in Primary Care: Considerations in the Selection of Antihyperglycemic Therapy for Older Patients With Type 2 Diabetes Mellitus: A Focus on Newer Therapies.

  2015cites this paper
• Subclinical Hypothyroidism and Type 2 Diabetes: A Systematic Review and Meta-Analysis

  2015cites this paper
• Pharmacogenetics: Implications for Modern Type 2 Diabetes Therapy.

  2015cites this paper
• A nomogram to estimate the HbA1c response to different DPP-4 inhibitors in type 2 diabetes: a systematic review and meta-analysis of 98 trials with 24 163 patients

  2015cites this paper
• Clinical Characteristics and Metabolic Predictors of Rapid Responders to Dipeptidyl Peptidase-4 Inhibitor as an Add-on Therapy to Sulfonylurea and Metformin

  2015cites this paper
• Predictive Factors for Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes Mellitus

  2015cites this paper
• Cardiometabolic Effects of a New Class of Antidiabetic Agents.

  2015cites this paper
• Hot Topics in Primary Care: Management of Opioid-induced Constipation.

  2015cites this paper
• Individualizing therapy: Do we have the tools to do it? 个体化治疗：我们有具体的执行方法吗？

  2015cites this paper
• Десять новых мишеней для разработки лекарственных средств для лечения СД2 и метаболического синдрома

  2015cites this paper
• Who would really benefit from DPP-4 inhibitors?

  2014cites this paper
• Incretin-based therapies, glucometabolic health and endovascular inflammation.

  2014cites this paper
• Reshaping diabetes care: the fundamental role of dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 receptor agonists in clinical practice.

  2013cites this paper
• What are the preferred strategies for control of glycaemic variability in patients with type 2 diabetes mellitus?

  2013cites this paper
• A novel model-based meta-analysis to indirectly estimate the comparative efficacy of two medications: an example using DPP-4 inhibitors, sitagliptin and linagliptin, in treatment of type 2 diabetes mellitus

  2013cites this paper
• Effect of Vildagliptin on Glucose and Insulin Concentrations During a 24-Hour Period in Type 2 Diabetes Patients with Different Ranges of Baseline Hemoglobin A1c Levels

  2013cites this paper
• Clinically relevant reductions in HbA1c without hypoglycaemia: results across four studies of saxagliptin

  2013cites this paper
• Incretin-Based Therapies: Focus on Effects Beyond Glycemic Control Alone

  2013cites this paper
• Profile of vildagliptin in type 2 diabetes: efficacy, safety, and patient acceptability

  2013cites this paper
• Cardiovascular Effects of Dipeptidyl Peptidase-4 Inhibitors: From Risk Factors to Clinical Outcomes

  2013cites this paper
• Cardiovascular effects of gliptins

  2013cites this paper
• Sodium-Glucose Co-Transporter 2 Inhibitors and the Potential for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes Mellitus

  2013cites this paper
• Cardiovascular effects of DPP-4 inhibitors : from risk factors to clinical outcomes

  2013cites this paper
• Evolution of Gliptins Over the Last 5 Years

  2013cites this paper
• Predictive clinical characteristics for the efficacy of vildagliptin monotherapy in Japanese patients with type 2 diabetes mellitus: a multicenter study

  2013cites this paper
• Comparative Clinical Pharmacokinetics of Dipeptidyl Peptidase-4 Inhibitors

  2012cites this paper
• Drug Class Review Newer Diabetes Medications, TZDs, and Combinations Single Drug Addendum: Linagliptin

  2012cites this paper
• Individualized Treatment of Type 2 Diabetes Mellitus Using Noninsulin Agents: Clinical Considerations for the Primary Care Physician

  2012cites this paper
• Serum level of soluble CD26/dipeptidyl peptidase-4 (DPP-4) predicts the response to sitagliptin, a DPP-4 inhibitor, in patients with type 2 diabetes controlled inadequately by metformin and/or sulfonylurea.

  2012cites this paper
• A review of gliptins in 2011

  2012cites this paper
• The effect of linagliptin on glycaemic control and tolerability in patients with type 2 diabetes mellitus: a systematic review and meta‐analysis

  2012cites this paper
• Managing Diabetes in the Middle-Aged Patient When Loss of Glycemic Control Occurs

  2012cites this paper
• Continuous glucose profiles with vildagliptin versus sitagliptin in add-on to metformin: results from the randomized Optima study.

  2012cites this paper
• Evolving Therapeutic Options for Type 2 Diabetes Mellitus: An Overview

  2012cites this paper
• Managing Diabetes From First Diagnosis

  2012cites this paper
• Predicting efficacy of dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes: Association of glycated hemoglobin reduction with serum eicosapentaenoic acid and docosahexaenoic acid levels

  2012cites this paper
• Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors.

  2012cites this paper
• Predictors of Emergency Department and Outpatient Visits for Hypoglycemia in Type 2 Diabetes: An Analysis of a Large US Administrative Claims Database

  2012cites this paper
• Dipeptidyl Peptidase-4 Inhibitors in the Elderly: More Benefits or Risks?

  2012influential citation
• DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials.

  2012cites this paper
• Tolerability of dipeptidyl peptidase-4 inhibitors: a review.

  2011cites this paper
• DPP-4 Inhibitors and Lipids: Systematic Review and Meta-Analysis

  2011cites this paper
• Drug discovery for type 2 diabetes mellitus and metabolic syndrome : ten novel biological targets

  year unknowncites this paper